Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Mycophenolate Mofetil for the Treatment of Systemic Sclerosis

Author(s): Manisha Naik, Max Shenin and Chris T. Derk

Volume 5, Issue 2, 2008

Page: [134 - 136] Pages: 3

DOI: 10.2174/157018008783928454

Price: $65

Abstract

Mycophenolate mofetil, an inosine monophosphate dehydrogenase inhibitor, that inhibits the de novo pathway of guanosine nucleotide synthesis, inhibits proliferative responses of T and B lymphocytes as well as antibody production by B-lymphocytes. It is indicated for the prophylaxis of organ rejection after allogeneic cardiac, hepatic and renal transplants. It has also been recently used with good success in patients with lupus nephritis. Based on these actions mycophenolate mofetil appears to be a novel agent in the treatment of systemic sclerosis.

Keywords: Mycophenolate mofetil, Mycophenolic acid, Fibsosis, Systemic sclerosis, Scleroderma, Treatment


© 2024 Bentham Science Publishers | Privacy Policy